First Light Asset Management LLC Acquires 1,485,664 Shares of TriSalus Life Sciences, Inc. $TLSI

First Light Asset Management LLC raised its holdings in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) by 29.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,552,491 shares of the company’s stock after purchasing an additional 1,485,664 shares during the period. TriSalus Life Sciences accounts for about 1.8% of First Light Asset Management LLC’s holdings, making the stock its 20th biggest position. First Light Asset Management LLC owned 10.64% of TriSalus Life Sciences worth $29,814,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of TLSI. BlackRock Inc. bought a new position in TriSalus Life Sciences in the 2nd quarter worth approximately $12,099,000. Perkins Capital Management Inc. purchased a new position in TriSalus Life Sciences in the 1st quarter valued at approximately $920,000. Nantahala Capital Management LLC bought a new stake in TriSalus Life Sciences during the 2nd quarter valued at $4,550,000. Wasatch Advisors LP bought a new stake in TriSalus Life Sciences during the 1st quarter valued at $5,752,000. Finally, Empire Financial Management Company LLC lifted its position in shares of TriSalus Life Sciences by 316.9% during the first quarter. Empire Financial Management Company LLC now owns 300,275 shares of the company’s stock worth $1,201,000 after acquiring an additional 228,248 shares in the last quarter. Institutional investors own 2.58% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on TLSI shares. Wall Street Zen upgraded TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research report on Sunday, August 23rd. Lake Street Capital dropped their price objective on TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Weiss Ratings restated a “sell (e+)” rating on shares of TriSalus Life Sciences in a research note on Friday, August 7th. Finally, HC Wainwright assumed coverage on TriSalus Life Sciences in a report on Wednesday. They set a “buy” rating and a $11.00 target price for the company. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $8.67.

TriSalus Life Sciences Stock Performance

NASDAQ TLSI opened at $4.76 on Thursday. The company’s 50 day simple moving average is $4.75 and its two-hundred day simple moving average is $4.33. The company has a debt-to-equity ratio of 5.05, a current ratio of 5.35 and a quick ratio of 4.97. TriSalus Life Sciences, Inc. has a 1 year low of $2.20 and a 1 year high of $7.95. The stock has a market capitalization of $293.12 million, a PE ratio of -3.66 and a beta of 0.44.

TriSalus Life Sciences (NASDAQ:TLSI) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.16) EPS for the quarter, meeting analysts’ consensus estimates of ($0.16). The firm had revenue of $11.41 million for the quarter, compared to analysts’ expectations of $10.27 million.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.